Entera Health Presents Possible New IBS Therapy

At the Experimental Biology 2013 meeting held in Boston April 20 to 24, Entera Health presented nonclinical studies demonstrating oral serum-derived bovine immunoglobulin/protein isolate (SBI) as a promising treatment for irritable bowel syndrome.

Advertisement

Sign up for our FREE GI E-Weekly for more coverage like this sent to your inbox!

SBI promotes bone density and lean body mass growth, allowing for increased nutrient absorption.

Entera Health is a biotherapeutics company focused on developing treatments for gastroenterology, oncology and immune disorder conditions.

More Articles on Gastroenterology:
Innotex Receives Patent for Colon Cancer Suturing System
Heartland Regional Medical Center Opens Gastroenterology & Hepatology Clinic
Ferring Pharmaceuticals Launches Colon Cancer Awareness Campaign

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.